Literature DB >> 8457646

Automated determination of cross-linked fibrin derivatives in plasma.

M J Elms1, P G Bundesen, D Rowbury, S Goodall, N Wakeham, J A Rowell, C J Hillyard, D B Rylatt.   

Abstract

Automated assays for the measurement of cross-linked fibrin derivatives in plasma (XL-FbDP) have been developed utilizing latex beads coated with anti-D dimer monoclonal antibody (DD-3B6/22) for both the Cobas Fara Chemistry Centrifugal and the Cobas Mira analysers (Roche, Basle, Switzerland). The analysers were programmed to mix plasma and latex reagent simultaneously and analyse absorbance changes over a 10-15 min period. Results were interpolated by the analyser from a standard curve derived from a polymer of D-dimer. Both assays had high precision (< 5% CV) for values between 100 and 1000 ng/ml and provided clear discrimination between normal samples and samples from patients suffering from the thrombotic diseases, DVT/PE and DIC. The results obtained for XL-FbDP determination with both methods compared well with established methods: a high correlation was obtained with a semi-quantitative manual latex method for both the Fara (r = 0.92) and Mira (r = 0.83) and correlations (r) of 0.81 (Fara) and 0.84 (Mira) were obtained with an enzyme immunoassay (EIA). Correlation between the two automated procedures was high (r = 0.96). The automated method will enable laboratories to provide a rapid and accurate quantitation of XL-FbDP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8457646

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  2 in total

1.  Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.

Authors:  Marcel Schouten; Koenraad F van der Sluijs; Bruce Gerlitz; Brian W Grinnell; Joris J T H Roelofs; Marcel M Levi; Cornelis van 't Veer; Tom van der Poll
Journal:  Crit Care       Date:  2010-04-14       Impact factor: 9.097

2.  Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Authors:  Marcel Schouten; Cornelis van't Veer; Joris J T H Roelofs; Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.